What is Acumen Pharmaceuticals, Inc. (ABOS) stock price today?

Acumen Pharmaceuticals, Inc. (ABOS) is currently trading at $2.14, up 1.9% today.

What is ABOS P/E ratio?

Acumen Pharmaceuticals, Inc.'s P/E ratio is -1.24. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ABOS return on equity (ROE)?

Acumen Pharmaceuticals, Inc.'s return on equity (ROE) is -136.27%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Acumen Pharmaceuticals, Inc.'s market cap?

Acumen Pharmaceuticals, Inc. has a market capitalization of $154.57M.

NASDAQ · Biotechnology

Acumen Pharmaceuticals, Inc. (ABOS) Stock

$2.14 +1.90% NASDAQ: ABOS Healthcare

Valuation

Metric	Value
Price	$2.14
Market Cap	$154.57M
P/E Ratio	-1.24
P/B Ratio	2.57
P/S Ratio	0.00
EPS (TTM)	$-2.00
52-Week High	$3.60
52-Week Low	$1.50
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-136.27%
ROA	-90.55%
ROCE	-152.43%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.55
Current Ratio	4.07

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-20.0M	$-45.0M	$-61.0M	$-114.0M	$-124.0M
Net Profit	$-101.0M	$-43.0M	$-52.0M	$-102.0M	$-121.0M
EPS	$-2.63	$-1.06	$-1.08	$-1.71	$-2.00
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$230.0M	$197.0M	$310.0M	$239.0M	$123.0M
Total Liabilities	$5.0M	$8.0M	$43.0M	$57.0M	$52.0M
Cash	$122.0M	$130.0M	$67.0M	$36.0M	$54.0M
Borrowings	$0	$0	$28.0M	$30.0M	$31.0M

Latest News

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy Zacks · Jul 15, 2026 Acumen Pharmaceuticals Shows Early Alzheimer’s Disease Insights Exec Edge · Jul 15, 2026 Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year? Zacks · Jul 15, 2026 Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 GlobeNewswire · Jul 15, 2026 Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs ACCESS Newswire · Jul 9, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-18.0M	$-35.0M	$-43.0M	$-86.0M	$-116.0M
Investing Cash Flow	$-104.0M	$39.0M	$-172.0M	$48.0M	$134.0M
Financing Cash Flow	$2.0M	$0	$0	$0	$0
Net Cash Flow	$78.0M	$8.0M	$-63.0M	$-31.0M	$18.0M
Free Cash Flow	$-18.0M	$-35.0M	$-43.0M	$-86.0M	$-116.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.04
EV / EBITDA	-1.19
FCF Yield	-62.29%
Quick Ratio	2.47
Interest Coverage	-24.41
Return 1Y	69.80%
Return 3Y	-59.71%
Return 5Y	-85.38%

Ownership

Insiders Held6.80%

Institutions Held64.20%

Institutions Float Held68.88%

Institutional Holder	Shares	Report Date
RA Capital Management, L.P.	20,992,669	2026-03-31
Sands Capital Alternatives, LLC	3,720,105	2026-03-31
Alyeska Investment Group, L.p.	2,454,754	2026-03-31
Franklin Resources, Inc.	2,305,096	2026-03-31
Adar1 Capital Management, LLC	2,156,334	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACTUActuate Therapeutics, Inc.	$0.61	-10.13%	-0.92	$14.60M	0.00%
AGENAgenus Inc.	$7.67	+1.72%	3.66	$319.40M	0.00%
ALECAlector, Inc.	$2.08	+2.97%	-1.84	$230.93M	0.00%
FATEFate Therapeutics, Inc.	$2.18	+2.35%	-2.21	$254.10M	0.00%
INOInovio Pharmaceuticals, Inc.	$1.15	+5.50%	-1.00	$79.46M	0.00%

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. is led by CEO Daniel J. O'Connell, employs 61 people, headquartered in US, publicly traded since 2021.

Acumen Pharmaceuticals, Inc. (ABOS) stock trades at $2.14 with a market capitalization of $154.57M. The stock is valued at a price-to-earnings (P/E) ratio of -1.24, price-to-book of 2.57, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.50 and $3.60, and currently trades 40.6% below its 52-week high.

On profitability, Acumen Pharmaceuticals, Inc. generates a return on equity (ROE) of -136.27%, return on capital employed of -152.43%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides